Bionano Genomics, Inc. (BNGO) - Dilution Analysis

10-Q filing | 11.0M shares outstanding

S-3 filing: BNGO filed an S-3 form on 2026-05-08 for a shelf offering of up to $400,000,000 in various securities, including common stock, preferred stock, and debt securities.

10-K filing | 11.1M shares outstanding

10-Q filing | 10.2M shares outstanding

10-Q filing | 4.7M shares outstanding

10-Q filing | 3.4M shares outstanding

10-K filing | 3.0M shares outstanding

8-K filing: Stock split 1:60 | Outstanding: 101,993,225 → 1,699,887

S-3/A filing: This is an S-3/A filing on 2025-01-08 for a shelf offering of up to 50,555,556 common shares, comprising (i) up to 45,555,556 Conversion Shares and (ii) 5,000,000 Private Placement Shares. The company will not receive any proceeds.

8-K filing: Bionano Genomics, Inc. entered into a securities purchase agreement to issue and sell 22,900,000 shares of common stock, pre-funded warrants to purchase 16,782,540 shares, and warrants to purchase 39,682,540 shares in a registered direct offering, with gross proceeds expected to be approximately $10.0 million. ($9.98M proceeds)

8-K filing: Bionano Genomics, Inc. entered into a settlement agreement and amendment relating to its outstanding senior secured convertible debentures, reducing the conversion price to $0.27 and issuing 5,000,000 new shares to investors.

S-3 filing: This is an S-3 filing for a shelf offering of common stock by selling securityholders.

10-Q filing | 102.0M shares outstanding

8-K filing: Bionano Genomics, Inc. entered into a securities purchase agreement to issue and sell 9,881,113 shares of common stock, Series C warrants to purchase up to 9,881,113 shares, and Series D warrants to purchase up to 9,881,113 shares in a registered direct offering at a combined purchase price of $0.3039 per share, with gross proceeds expected to be approximately $3.0 million. ($3.0M proceeds)

10-Q filing | 86.0M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 35,026,272 shares of common stock issuable upon exercise of warrants by selling securityholders.

8-K filing: Bionano Genomics, Inc. entered into a securities purchase agreement to issue and sell shares of common stock and warrants in a registered direct offering and concurrent private placement, expecting to receive approximately $10.0 million in gross proceeds. ($10.0M proceeds)

S-3 filing: This S-3 filing registers the resale of up to 12,250,000 shares of common stock by selling securityholders, comprising 2,250,000 upfront shares and 10,000,000 shares issuable upon conversion of debentures.

8-K filing: Bionano Genomics, Inc. completed a private placement offering on May 24, 2024, selling 2,250,000 shares of common stock and Senior Secured Convertible Debentures for an aggregate purchase price of $18,000,000, with net proceeds of approximately $17.9 million used primarily to redeem a Senior Secured Convertible Note. ($18.0M proceeds)

10-Q filing | 66.9M shares outstanding

8-K filing: Bionano Genomics, Inc. filed a prospectus supplement regarding the sale and issuance of 6,536,682 shares of common stock, pre-funded warrants to purchase 2,196,944 shares of common stock, and warrants to purchase 8,733,626 shares of common stock in a registered direct offering.

8-K filing: Bionano Genomics, Inc. entered into a securities purchase agreement with institutional investors to issue and sell shares of common stock, pre-funded warrants, and warrants in a registered direct offering expected to close on April 8, 2024, with gross proceeds of approximately $10.0 million. ($10.0M proceeds)

10-K filing | 54.7M shares outstanding

8-K filing: Bionano Genomics, Inc. entered into a letter agreement with High Trail Special Situations LLC to redeem a portion of outstanding notes for a total redemption payment of $31,812,450 and amended the Initial Registered Note to modify liquidity covenants and partial redemption dates.

10-Q filing | 35.0M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to $35,000,000 aggregate principal amount of Senior Secured Convertible Notes due 2025 and up to 12,221,738 shares of common stock issuable upon conversion of the notes by the Selling Securityholder.

8-K filing: Bionano Genomics, Inc. entered into a securities purchase agreement with High Trail Special Situations LLC for the issuance and sale of senior secured convertible notes and warrants in a registered offering and a concurrent private placement, expecting net proceeds of approximately $75.6 million for working capital and general corporate purposes.

10-Q filing | 35.3M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 302,045,000 → 30,204,500

10-Q filing | 302.0M shares outstanding

S-3/A filing: This is an S-3/A filing to amend Item 16 of Part II to file certain exhibits to the registration statement.

8-K filing: The company filed a Certificate of Designation for Series A Preferred Stock, designating one share with 3,000,000,000 votes on a Reverse Stock Split Proposal, and amended bylaws to reduce the quorum requirement for stockholder meetings. They issued one share of Series A Preferred Stock to an accredited investor.

S-3 filing: The company is filing an S-3 to offer and sell up to $400,000,000 of any combination of common stock, preferred stock, and debt securities from time to time.

10-K filing | 289.2M shares outstanding

10-Q filing | 289.7M shares outstanding

10-Q filing | 285.6M shares outstanding

10-Q filing | 284.6M shares outstanding

10-K filing | 289.6M shares outstanding

10-Q filing | 280.2M shares outstanding

10-Q filing | 278.9M shares outstanding

10-Q filing | 278.8M shares outstanding

10-K filing | 278.7M shares outstanding

8-K filing: Bionano Genomics, Inc. entered into an underwriting agreement for the issuance and sale in a public offering of 33,333,350 shares of the Company's common stock at a price of $6.00 per share, with net proceeds expected to be approximately $187.3 million. ($187.3M proceeds)

8-K filing: Bionano Genomics, Inc. announced a public offering of 29,016,393 shares of common stock at a price of $3.05 per share, with the Underwriters having an option to purchase up to 4,352,458 additional shares, with the offering expected to close on January 12, 2021. ($82.8M proceeds)

10-Q filing | 153.2M shares outstanding

8-K filing: Christopher Stewart was appointed as Chief Financial Officer of Bionano Genomics, Inc., effective September 1, 2020, and will be granted stock options to purchase 350,000 and 225,000 shares of the Company's common stock.

8-K filing: Bionano Genomics, Inc. acquired Lineagen, Inc. through a merger, issuing 6,167,510 shares of common stock as consideration, subject to adjustments, and adopted the Bionano Genomics, Inc. 2020 Inducement Plan, reserving 2,100,000 shares of common stock for issuance.

S-3 filing: The company is filing an S-3 to register a shelf offering of up to $125,000,000 of common stock, preferred stock, and debt securities.

10-Q filing | 138.5M shares outstanding

S-3/A filing: This S-3/A filing covers the offer and resale of 872,601 shares of common stock by selling stockholders; the company will not receive any proceeds from the sale.

S-3 filing: This is an S-3 filing for the offer and resale of common stock by selling stockholders, with the company not receiving any proceeds from the sale.

10-Q filing | 83.9M shares outstanding

8-K filing: Bionano Genomics, Inc. completed a public offering of 16,896,000 shares of common stock and pre-funded warrants to purchase 37,650,000 shares of common stock, along with accompanying common warrants to purchase up to 54,546,000 shares of common stock, for gross proceeds of approximately $18.0 million. ($18.0M proceeds)

S-1/A filing: The company is offering 34,886,000 shares of common stock, pre-funded warrants, and common warrants to purchase an aggregate of 34,886,000 shares of common stock.

S-1 filing: The company is offering 17,648,000 shares of its common stock and common warrants to purchase an aggregate of 17,648,000 shares of its common stock, and also offering pre-funded warrants to certain purchasers.

S-3 filing: This prospectus covers the offer and resale by Innovatus Life Sciences Lending Fund I, LP, or Innovatus, and Innovatus Life Sciences Offshore Fund I-A, LP, or Innovatus Offshore, of up to an aggregate of 1,141,408 shares of our common stock, which includes 161,987 shares of our common stock issuable upon the exercise of warrants, issued to Innovatus and Innovatus Offshore in private transactions.

10-K filing | 37.8M shares outstanding

8-K filing: Bionano Genomics, Inc. amended warrants with certain holders to adjust the exercise price to $0.75 for a limited time, and agreed to issue new warrants with an exercise price of $1.06 if all Original Warrants are exercised for cash during the Modified Exercise Price Term.